UNITY Biotechnology, Inc. Appoints Camille Landis as Senior Vice President of Corporate Development

May 14, 2018 at 4:05 PM EDT

SAN FRANCISCO, May 14, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Camille Landis as senior vice president of corporate development.

“Camille brings significant experience in building and leading corporate development organizations,” said Keith Leonard, chairman and chief executive officer of UNITY. “UNITY will be evaluating opportunities to extend our reach and to bring innovative medicines that can change the trajectory of aging and extend human healthspan, and we’re pleased to have Camille onboard to lead this process.”

Ms. Landis most recently served as chief business officer at Eidos Therapeutics, where she oversaw the company's corporate development and financing activities. Prior to Eidos, she was vice president of corporate development at Relypsa, where she was responsible for building and leading corporate development, alliance management and strategic planning. She led the sale process of Relypsa to Galencia for $1.5 billion and supported the company's IPO and financing activities, which raised over $475 million. She also led Relypsa's global partnering effort that resulted in a $165 million licensing agreement with Vifor Fresenius Medical Renal Pharma and a co-detailing agreement with Sanofi. Ms. Landis also led corporate development efforts at Affymax and held multiple positions in finance, business development and commercial operations. Earlier in her career, she served as a life sciences strategy consultant with Frontline Consulting, acquired by Navigant, and as an investment banking analyst with Piper Jaffray’s healthcare investment banking practice. Ms. Landis earned a MBA from the Haas School of Business at the University of California, Berkeley and a BA in biology from the University of St. Thomas.

About UNITY Biotechnology, Inc.
UNITY Biotechnology, Inc. is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. More information is available at www.unitybiotechnology.com.

Forward-Looking Statements
This press release contains forward-looking statements, including but not limited to statements related to our potential to bring multiple medicines to market to impact aging and extend human healthspan. Such forward-looking statements involve substantial risks and uncertainties that could cause UNITY’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including UNITY’s early stage of development and its understanding of senescence biology, the clinical trial enrollment process, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, UNITY’s ability to successfully protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations and the availability or commercial potential of UNITY’s product candidates. UNITY undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see UNITY’s recently filed Registration Statement on Form S-1 and any subsequent current and periodic reports filed with the Securities and Exchange Commission.

UNITY Biotechnology, Inc.Bob Goeltz
Chief Financial Officer

Canale CommunicationsJason Spark

Primary Logo

Source: Unity Biotechnology, Inc.